Genmab shares double on cancer trial wins
CNBC · RSS · · AI-summarised by FinFlash
Genmab's shares have doubled over three months following a string of successful cancer drug trial results. The Danish biotech is using those wins to strengthen its push to own more of the medicines it develops, rather than licensing them out to larger partners. The rally reflects growing investor confidence in that strategy shift.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.